TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)
Brief Summary: This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1
C: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
D: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)
Brief Summary: This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).


Options:
A: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg
B: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
C: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
D: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)
Brief Summary: This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Atacicept 25 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 25 mg | Arm Label: Atacicept 75 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 75 mg | Arm Label: Atacicept 150 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Arm Label: Atacicept 150 mg (Without Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Intervention Type: DRUG; Name: Atacicept 25 mg; Assigned to Arm(s): Atacicept 25 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 75 mg; Assigned to Arm(s): Atacicept 75 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (Without Loading)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)
Brief Summary: The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate, Drug: atorvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sevelamer, Drug: atorvastatin | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sevelamer; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1, 2
B: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride
C: Arm Label: PA21 (2.5 g tablet); Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: PA21-1 (1.25 g tablet); Type: OTHER; Interventions: Drug: PA21-1 (1.25 g tablet containing 250 mg iron) | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 (2.5 g tablet) | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate | Intervention Type: DRUG; Name: PA21-1 (1.25 g tablet containing 250 mg iron); Assigned to Arm(s): PA21-1 (1.25 g tablet)
D: Arm Label: Sevelamer; Type: OTHER; Interventions: Drug: Sevelamer, Drug: calcium acetate | Arm Label: calcium acetate; Type: OTHER; Interventions: Drug: calcium acetate | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): Sevelamer, calcium acetate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease
Brief Summary: The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.


Options:
A: Arm Label: K2CG chewing gum (20 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (20mg chitosan) | Arm Label: K2CG chewing gum (60 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (60mg chitosan) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: K2CG chewing gum (20mg chitosan); Assigned to Arm(s): K2CG chewing gum (20 mg chitosan) | Intervention Type: OTHER; Name: K2CG chewing gum (60mg chitosan); Assigned to Arm(s): K2CG chewing gum (60 mg chitosan)
B: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: SBR759A | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 4; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 5; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 4 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 5
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SBR759 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer HCl | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer HCl | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer HCl | Intervention Type: DRUG; Name: SBR759; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 2
D: Arm Label: PhosLo; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): PhosLo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Postpartum Weight Loss in Overweight Women
Brief Summary: The purpose of this study is to evaluate, in a five-year randomized controlled trial, the efficacy of an intervention (AMP - ACTIVE MOTHERS POSTPARTUM) to increase physical activity and promote a healthy diet (decreased calorie and fat intake) for weight loss among postpartum women who were overweight or obese prior to pregnancy. The hypothesis is that the proportion of women losing at least 10% of BMI from baseline to 12 months post-intervention will be significantly greater in the AMP intervention arm than in the minimal care arm.


Options:
A: Arm Label: Web-based only (WO) weight intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention | Arm Label: WO & peer-led discussion board (WD); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO plus peer-led discussion board (WD) | Arm Label: WO & professional email counseling (WE); Type: EXPERIMENTAL; Interventions: Behavioral: Experimental: Web-based only (WO) weight intervention, Behavioral: Experimental: WO & professional email counseling (WE) | Intervention Type: BEHAVIORAL; Name: Experimental: Web-based only (WO) weight intervention; Assigned to Arm(s): WO & peer-led discussion board (WD), WO & professional email counseling (WE), Web-based only (WO) weight intervention | Intervention Type: BEHAVIORAL; Name: Experimental: WO plus peer-led discussion board (WD); Assigned to Arm(s): WO & peer-led discussion board (WD) | Intervention Type: BEHAVIORAL; Name: Experimental: WO & professional email counseling (WE); Assigned to Arm(s): WO & professional email counseling (WE)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2
C: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Arm Label: Cognitive Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: moderate exercise and healthy, low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate exercise and healthy, low-fat diet; Assigned to Arm(s): Lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Postpartum Weight Loss in Overweight Women
Brief Summary: The purpose of this study is to evaluate, in a five-year randomized controlled trial, the efficacy of an intervention (AMP - ACTIVE MOTHERS POSTPARTUM) to increase physical activity and promote a healthy diet (decreased calorie and fat intake) for weight loss among postpartum women who were overweight or obese prior to pregnancy. The hypothesis is that the proportion of women losing at least 10% of BMI from baseline to 12 months post-intervention will be significantly greater in the AMP intervention arm than in the minimal care arm.


Options:
A: Arm Label: Parents As Teachers + Lifestyle Int.; Type: EXPERIMENTAL; Interventions: Behavioral: Parents As Teachers Plus (PAT+) | Arm Label: Standard Parents as Teachers (PAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Parents As Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Standard Parents As Teachers (PAT); Assigned to Arm(s): Standard Parents as Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Parents As Teachers Plus (PAT+); Assigned to Arm(s): Parents As Teachers + Lifestyle Int.
B: Arm Label: Education Home Visits; Type: EXPERIMENTAL; Interventions: Other: Education Home Visits | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Education Home Visits; Assigned to Arm(s): Education Home Visits
C: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: moderate exercise and healthy, low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate exercise and healthy, low-fat diet; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Lifestyle Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Balance after Baby Lifestyle Intervention Program | Arm Label: Post-gestational diabetes mellitus (GDM) Follow-up Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Balance after Baby Lifestyle Intervention Program; Assigned to Arm(s): Lifestyle Intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Postpartum Weight Loss in Overweight Women
Brief Summary: The purpose of this study is to evaluate, in a five-year randomized controlled trial, the efficacy of an intervention (AMP - ACTIVE MOTHERS POSTPARTUM) to increase physical activity and promote a healthy diet (decreased calorie and fat intake) for weight loss among postpartum women who were overweight or obese prior to pregnancy. The hypothesis is that the proportion of women losing at least 10% of BMI from baseline to 12 months post-intervention will be significantly greater in the AMP intervention arm than in the minimal care arm.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: moderate exercise and healthy, low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate exercise and healthy, low-fat diet; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Conservative Treatment of Postprostatectomy Incontinence
Brief Summary: The primary purpose of this study is to test the effectiveness, impact on quality of life, and durability of non-surgical therapies for incontinence persisting at least one year after surgery. The study is a a prospective, controlled, randomized trial comparing an 8-week, multi-component behavioral training program (pelvic floor muscle exercises, self-monitoring with bladder diaries, regular office visits, bladder control techniques, and fluid management) to the same program with the addition of biofeedback and pelvic muscle electrical stimulation.


Options:
A: Arm Label: BF+SUPPORT; Type: EXPERIMENTAL; Interventions: Behavioral: BF+SUPPORT | Arm Label: BF+PHONE; Type: EXPERIMENTAL; Interventions: Behavioral: BF+PHONE | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BF+SUPPORT; Assigned to Arm(s): BF+SUPPORT | Intervention Type: BEHAVIORAL; Name: BF+PHONE; Assigned to Arm(s): BF+PHONE
B: Arm Label: PILATES; Type: EXPERIMENTAL; Interventions: Other: Pilates | Arm Label: PFMT and AES; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT and AES | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Pilates; Assigned to Arm(s): PILATES | Intervention Type: OTHER; Name: PFMT and AES; Assigned to Arm(s): PFMT and AES | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: study group; Type: ACTIVE_COMPARATOR; Interventions: Other: whole body vibration | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: whole body vibration; Assigned to Arm(s): study group
D: Arm Label: Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy | Arm Label: Behavioral Therapy Plus Technologies; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy, Device: Pelvic Floor Electrical Stimulation, Behavioral: Biofeedback | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Other: No Treatment | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Behavioral Therapy, Behavioral Therapy Plus Technologies | Intervention Type: DEVICE; Name: Pelvic Floor Electrical Stimulation; Assigned to Arm(s): Behavioral Therapy Plus Technologies | Intervention Type: BEHAVIORAL; Name: Biofeedback; Assigned to Arm(s): Behavioral Therapy Plus Technologies | Intervention Type: OTHER; Name: No Treatment; Assigned to Arm(s): Placebo Comparator

Answer: D